collection
https://read.qxmd.com/read/37542422/the-impact-of-sglt2-inhibitors-on-cardiovascular-outcomes-in-patients-with-heart-failure-with-preserved-ejection-fraction
#1
REVIEW
Jessica A Starr, Nathan A Pinner
OBJECTIVE: To evaluate the role of sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with heart failure with preserved ejection fraction (HFpEF). DATA SOURCES: A literature search of PubMed, the Cochrane Library, and Google Scholar databases (January 2015 to June 20, 2023) was performed with keywords: sodium-glucose co-transporter 2 inhibitors OR SGLT2 inhibitors OR bexagliflozin OR canagliflozin OR dapagliflozin OR empagliflozin OR ertugliflozin OR sotagliflozin AND heart failure OR heart failure with preserved ejection fraction, and terms related to CV outcomes including cardiovascular death, hospitalization, hospitalization for heart failure, mortality, death, and major adverse cardiovascular event (MACE)...
August 5, 2023: Annals of Pharmacotherapy
https://read.qxmd.com/read/37743672/keeping-it-current-a-review-of-treatment-options-for-the-management-of-supraventricular-tachycardia
#2
REVIEW
Patrick Tednes, Samantha Marquardt, Shannon Kuhrau, Kristin Heagler, Megan Rech
OBJECTIVE: To review treatment options and updates that exist for the management of paroxysmal supraventricular tachycardia (PSVT). DATA SOURCES: A literature search of PubMed was performed including articles from 1974 to June 2023 using the terms: arrhythmias , adenosine , verapamil , diltiazem , esmolol , propranolol , metoprolol , beta-blockers , amiodarone , PSVT , synchronized cardioversion , methylxanthines , dipyridamole , pediatrics , heart transplant , and pregnancy ...
September 24, 2023: Annals of Pharmacotherapy
https://read.qxmd.com/read/26209466/novel-vagal-maneuver-technique-for-termination-of-supraventricular-tachycardias
#3
JOURNAL ARTICLE
Haluk Un, Mehmet Dogan, Omer Uz, Zafer Isilak, Mehmet Uzun
Hemodynamically unstable patients with supraventricular tachycardias (SVTs) should be treated with electrical cardioversion. If the patient is stable, acute termination of tachycardia can be achieved by vagal maneuvers or medical therapy. The Valsalva maneuver, carotid massage, and ice to the face are the most common vagal maneuvers. In our experience with patients, we observed that vagal stimulation increases with lying backward. Our suggested maneuver is based on quickly lying backward, from a seated position...
January 2016: American Journal of Emergency Medicine
https://read.qxmd.com/read/31378333/bradyarrhythmias-for-the-internist
#4
REVIEW
Noha Elbanhawy, Shajil Chalil, Khalid Abozguia
In this article, the authors review the different types of sinus node and atrioventricular node diseases that lead to bradyarrhythmias with their associated symptoms, the diagnostic investigations needed to assess the degree of disease, and the therapeutic management, including the indications for permanent pacing.
September 2019: Medical Clinics of North America
https://read.qxmd.com/read/31406442/head-rules-over-the-heart-cardiac-manifestations-of-cerebral-disorders
#5
REVIEW
Ajay Prasad Hrishi, Karen Ruby Lionel, Unnikrishnan Prathapadas
The Brain-Heart interaction is becoming increasingly important as the underlying pathophysiological mechanisms become better understood. "Neurocardiology" is a new field which explores the pathophysiological interplay of the brain and cardiovascular systems. Brain-heart cross-talk presents as a result of direct stimulation of some areas of the brain, leading to a sympathetic or parasympathetic response or it may present as a result of a neuroendocrine response attributing to a clinical picture of a sympathetic storm...
July 2019: Indian Journal of Critical Care Medicine
https://read.qxmd.com/read/25089130/statin-therapy-for-primary-prevention-of-atrial-fibrillation-guided-by-chads2-cha2ds2vasc-score
#6
REVIEW
Chen-Ying Hung, Yu-Cheng Hsieh, Jin-Long Huang, Ching-Heng Lin, Tsu-Juey Wu
Atrial fibrillation (AF) is the most common arrhythmia and is associated with increased cardiovascular morbidity and mortality. The anti-arrhythmic effect of statins on AF prevention appears to be highly significant in most clinical studies. However, some discrepancies do exist among different clinical studies. Different clinical settings and types of stains used may explain these differences between trials. The CHADS2 and CHA2DS2VASc scoring systems have been used for stroke risk stratification in AF patients...
July 2014: Korean Circulation Journal
https://read.qxmd.com/read/16403928/comparison-of-beta-blockers-amiodarone-plus-beta-blockers-or-sotalol-for-prevention-of-shocks-from-implantable-cardioverter-defibrillators-the-optic-study-a-randomized-trial
#7
RANDOMIZED CONTROLLED TRIAL
Stuart J Connolly, Paul Dorian, Robin S Roberts, Michael Gent, Steven Bailin, Eric S Fain, Kevin Thorpe, Jean Champagne, Mario Talajic, Benoit Coutu, Gerian C Gronefeld, Stefan H Hohnloser
CONTEXT: Implantable cardioverter defibrillator (ICD) therapy is effective but is associated with high-voltage shocks that are painful. OBJECTIVE: To determine whether amiodarone plus beta-blocker or sotalol are better than beta-blocker alone for prevention of ICD shocks. DESIGN, SETTING, AND PATIENTS: A randomized controlled trial with blinded adjudication of events of 412 patients from 39 outpatient ICD clinical centers located in Canada, Germany, United States, England, Sweden, and Austria, conducted from January 13, 2001, to September 28, 2004...
January 11, 2006: JAMA
https://read.qxmd.com/read/29621027/cardiac-output-monitoring-how-to-choose-the-optimal-method-for-the-individual-patient
#8
REVIEW
Bernd Saugel, Jean-Louis Vincent
PURPOSE OF REVIEW: To review the different methods available for the assessment of cardiac output (CO) and describe their specific indications in intensive care and perioperative medicine. RECENT FINDINGS: In critically ill patients, persistent circulatory shock after initial resuscitation is an indication for the assessment of CO to monitor the response to fluids and vasoactive agents. In patients with circulatory shock associated with right ventricular dysfunction, pulmonary artery hypertension, or acute respiratory distress syndrome, invasive CO monitoring using indicator dilution methods is indicated...
June 2018: Current Opinion in Critical Care
https://read.qxmd.com/read/27067085/should-patients-with-atrial-fibrillation-and-1-stroke-risk-factor-cha2ds2-vasc-score-1-in-men-2-in-women-be-anticoagulated-the-cha2-ds2-vasc-1-conundrum-decision-making-at-the-lower-end-of-the-risk-spectrum
#9
JOURNAL ARTICLE
https://read.qxmd.com/read/27067086/stroke-prevention-in-atrial-fibrillation-in-patients-with-chronic-kidney-disease
#10
REVIEW
Arman Qamar, Deepak L Bhatt
No abstract text is available yet for this article.
April 12, 2016: Circulation
https://read.qxmd.com/read/27073130/endurance-exercise-and-the-right-ventricle-weak-link-innocent-bystander-or-key-ingredient
#11
EDITORIAL
Meagan M Wasfy, Aaron L Baggish
No abstract text is available yet for this article.
May 17, 2016: Circulation
https://read.qxmd.com/read/27143546/recent-update-to-the-us-cholesterol-treatment-guidelines-a-comparison-with-international-guidelines
#12
REVIEW
Matthew Nayor, Ramachandran S Vasan
The 2013 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol guideline advocated several changes from the previous Adult Treatment Panel III guidelines. Assuming full implementation, the 2013 ACC/AHA guideline would identify ≈13 million Americans as newly eligible for consideration of statin therapy. Three features of the 2013 ACC/AHA guideline primarily responsible for these differences are the specific risk assessment tool endorsed, the risk threshold considered sufficient to warrant primary prevention statin therapy, and the decision not to include cholesterol treatment targets...
May 3, 2016: Circulation
https://read.qxmd.com/read/27143684/importance-of-clinical-worsening-of-heart-failure-treated-in-the-outpatient-setting-evidence-from-the-prospective-comparison-of-arni-with-acei-to-determine-impact-on-global-mortality-and-morbidity-in-heart-failure-trial-paradigm-hf
#13
RANDOMIZED CONTROLLED TRIAL
Naoki Okumura, Pardeep S Jhund, Jianjian Gong, Martin P Lefkowitz, Adel R Rizkala, Jean L Rouleau, Victor C Shi, Karl Swedberg, Michael R Zile, Scott D Solomon, Milton Packer, John J V McMurray
BACKGROUND: Many episodes of worsening of heart failure (HF) are treated by increasing oral therapy or temporary intravenous treatment in the community or emergency department (ED), without hospital admission. We studied the frequency and prognostic importance of these episodes of worsening in the Prospective Comparison of ARNI (angiotensin-receptor-neprilysin inhibitor) with ACEI (angiotensin-converting enzyme inhibitor) to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF)...
June 7, 2016: Circulation
https://read.qxmd.com/read/27217435/individualizing-duration-of-dual-antiplatelet-therapy-after-acute-coronary-syndrome-or-percutaneous-coronary-intervention
#14
REVIEW
Akshay Bagai, Deepak L Bhatt, John W Eikelboom, G B John Mancini, Eric A Cohen, Ram Vijayaraghavan, Asim N Cheema, Jacob A Udell, Joel Niznick, Jean-Francois Tanguay, Subodh Verma, Shamir R Mehta
No abstract text is available yet for this article.
May 24, 2016: Circulation
https://read.qxmd.com/read/26293770/vagal-modulation-of-atrial-fibrillation
#15
LETTER
Asif Machhada, Alexander V Gourine, Gareth L Ackland
No abstract text is available yet for this article.
August 25, 2015: Journal of the American College of Cardiology
https://read.qxmd.com/read/26314543/reply-duration-of-triple-therapy-in-patients-requiring-oral-anticoagulation-after-drug-eluting-stent-implantation
#16
LETTER
Nikolaus Sarafoff, Robert A Byrne, Julinda Mehilli, Dirk Sibbing, Steen D Kristensen, Karl-Ludwig Laugwitz, Michael Maeng, Adnan Kastrati
No abstract text is available yet for this article.
September 1, 2015: Journal of the American College of Cardiology
https://read.qxmd.com/read/26314542/duration-of-triple-therapy-in-patients-requiring-oral-anticoagulation-after-drug-eluting-stent-implantation
#17
LETTER
Femi Philip
No abstract text is available yet for this article.
September 1, 2015: Journal of the American College of Cardiology
https://read.qxmd.com/read/12660669/effects-of-high-dose-furosemide-and-small-volume-hypertonic-saline-solution-infusion-in-comparison-with-a-high-dose-of-furosemide-as-bolus-in-refractory-congestive-heart-failure-long-term-effects
#18
RANDOMIZED CONTROLLED TRIAL
Giuseppe Licata, Pietro Di Pasquale, Gaspare Parrinello, Antonietta Cardinale, Angela Scandurra, Giuseppe Follone, Christiano Argano, Antonino Tuttolomondo, Salvatore Paterna
BACKGROUND: Diuretics have been accepted as first-line treatment in refractory congestive heart failure (CHF), but a lack of response to them is a frequent event. A randomized, single-blind study was performed to evaluate the effects of the combination of high-dose furosemide and small-volume hypertonic saline solution (HSS) infusion in the treatment of refractory New York Heart Association (NYHA) class IV CHF and a normosodic diet during follow-up. Materials and Methods One hundred seven patients (39 women and 68 men, age range 65-90 years) with refractory CHF (NYHA class IV) of different etiologies, who were unresponsive to high oral doses of furosemide, angiotensin-converting enzyme inhibitors, digitalis, and nitrates, were enrolled...
March 2003: American Heart Journal
https://read.qxmd.com/read/26201463/cangrelor-a-review-in-percutaneous-coronary-intervention
#19
REVIEW
Gillian M Keating
Cangrelor (Kengrexal(®), Kengreal(™)) is an intravenously administered P2Y12 receptor inhibitor. It is direct-acting and reversible, with a very rapid onset and offset of action. The randomized, double-blind, multinational, phase III CHAMPION PHOENIX trial compared the efficacy of intravenous cangrelor with that of oral clopidogrel in patients requiring percutaneous coronary intervention (PCI) for stable angina pectoris, a non-ST-segment elevation acute coronary syndrome or ST-segment elevation myocardial infarction (MI)...
August 2015: Drugs
https://read.qxmd.com/read/26177892/a-review-of-nebivolol-pharmacology-and-clinical-evidence
#20
REVIEW
Justin Fongemie, Erika Felix-Getzik
Nebivolol is a highly selective β1-adrenergic receptor antagonist with a pharmacologic profile that differs from those of other drugs in its class. In addition to cardioselectivity mediated via β1 receptor blockade, nebivolol induces nitric oxide-mediated vasodilation by stimulating endothelial nitric oxide synthase via β3 agonism. This vasodilatory mechanism is distinct from those of other vasodilatory β-blockers (carvedilol, labetalol), which are mediated via α-adrenergic receptor blockade...
August 2015: Drugs
label_collection
label_collection
5200
1
2
2015-08-17 16:50:56
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.